human d4

ABT-670 is a selective agonist of dopamine D4 receptor. For human D4, ferret D4, and rat D4, the EC50 values are 89 nM, 160 nM, and 93 nM , respectively.

L-741626 (3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole) 是D2多巴胺受体选择性拮抗剂，对人 D2、D3 和 D4 受体的Ki 分别为 2.4、100 和 220 nM。

Iloperidone (HP 873) 是一种D2 5-HT2受体拮抗剂，是非典型抗精神病药，可治疗精神分裂症。

Rupatadine(UR-12592,卢帕他定)是一种有效和可口服的PAF和组胺H1受体的双重拮抗剂，Ki 值分别为 0.55 μM 和 0.1 μM，能够缓解过敏症状并抗炎，可用于过敏性鼻炎和慢性荨麻疹。

Sonepiprazole 是D4多巴胺受体选择性拮抗剂，与rD4多巴胺受体，hD4.2多巴胺受体，rD2多巴胺受体和组胺H1受体结合的Ki 分别为 3.6、10.1、5147 和 7430 nM。

GR 103691 是选择性的多巴胺 D3受体拮抗剂，Ki=0.4 nM。它对人多巴胺 D3的选择性超过 D4和 D1的 100 倍以上。

Indomethacin-D4 is a deuterium labeled Indomethacin. Indomethacin is a potent and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.

L-745870 hydrochloride 是可透过血脑屏障的、选择性的、具有口服活性的多巴胺 D4受体拮抗剂，Ki=0.43 nM。它对 D2(Ki 为 960 nM) 和 D3(Ki 为 2300 nM) 受体的亲和力相对较弱，对 5-HT2受体，sigma 位点和 α-肾上腺素受体表现出中等亲和力。

L-745870 是一种可透过血脑屏障且具有口服活性、选择性和高效性的多巴胺 D4 受体拮抗剂，抑制 D2 受体、5-HT2 受体和 α-肾上腺素受体，可用于研究神经系统疾病。

Loxapine succinate (Loxapac) 是D2 D4多巴胺受体，5-羟色胺受体抑制剂，用于精神分裂症。

Fananserin 是一种有效的、特异性的、口服活性的 5-HT2 拮抗剂（大鼠 5-HT2A 的 Ki = 0.37 nM）。 Fananserin 是人 D4 受体的拮抗剂 (Ki = 2.93 nM)。

Verlukast is an (R)-enantiomer of MK-571 and a potent and selective LTD4 receptor antagonist. Verlukast showed [3H]leukotriene D4 binding in guinea-pig (IC50 = 3.1 +/- 0.5 nM) and human (IC50 = 8.0 +/- 3.0 nM) lung homogenates and dimethyl sulfoxide diffe

Loxapine 是 D2DR 和 D4DR 抑制剂和5-羟色胺能受体拮抗剂，是一种抗精神病药物，主要用于治疗精神分裂症。

ABT 724 trihydrochloride 是一种有效的选择性 D4 受体激动剂（EC50 = 12.4 nM，14.3 nM 和 23.2 nM，分别对人、大鼠和雪貂）。 ABT-724 trihydrochloride 可用于勃起功能障碍研究。

Iloperidone hydrochloride is a D(2) 5-HT(2) receptor antagonist. It is also an atypical antipsychotic for the treatment of schizophrenia symptoms.

SR 2640 hydrochloride 是白三烯 D4 和 E4 的竞争性拮抗剂，可用于研究人类哮喘中的白三烯。

L 741742 is an effective and highly selective antagonist of the D4 dopamine receptor (Ki: 1700, 770, and 3.5 nM at cloned human D2, D3, and D4 receptors).

SRA880 is a non-peptide somatostatin sst(1) receptor antagonist which displays a significantly lower affinity for the other human recombinant somatostatin receptors ( pK(d)= 6.0) or a wide range of neurotransmitter receptors, except for the human dopamine

SRA880 is a non-peptide antagonist of somatostatin sst1-receptor. SRA880 displayed significantly lower affinity for the other human recombinant somatostatin receptors ( pK(d) < or = 6.0). SRA880 shows a certain binding affinity to the human dopamine D4 re

SV-156 is a highly selective antagonist of dopamine receptor 2 (D2).

U-101958 Maleate is a ligand of dopamine D4 receptor. U-101958 Maleate also binds to a large sigma1 receptor-like component in SK-N-MC neuroblastoma cells and human cerebellum with high affinity.

14,15-Leukotriene D4 (14,15-LTD4) is a member of an alternate class of LTs synthesized by a pathway involving the dual actions of 15- and 12-lipoxygenases (15- and 12-LOs) on arachidonic acid via 15-HpETE and 14,15-LTA4 intermediates. 14,15-LTD4 is classified as an eoxin (EXD4), because it is formed mostly by eosinophils. However, mast cells and nasal polyps can synthesize 14,15-LTD4 as well. Little is known about the physiological actions of 14,15-LTD4. It has weak contractile activity on both guinea pig ileum and pulmonary parenchyma in contrast to the effects of 5-LO-derived LTs. However, in an in vitro permeability assay, 14,15-LTD4 can increase vascular permeability of human endothelial cell monolayers, with similar potency to that of 5-LO-derived LTs, resulting in plasma leakage, a hallmark of inflammation.

Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid . [1] It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.[2][3] RvD4, at 10 ng mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng mouse, diminishes neutrophil infiltration in response to S. aureus infection. [3] With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.[3] It also promotes the clearance of apoptotic neutrophils by human fibroblasts.[3] Reference：[1]. Serhan, C.N., and Savill, J. Resolution of inflammation: The beginning programs the end. Nature Immunology 6(12), 1191-1197 (2005).[2]. Arnardottir, H., Orr, S.K., Dalli, J., et al. Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal. Immunol. 9(3), 757-766 (2016).[3]. Winkler, J.W., Orr, S.K., Dalli, J., et al. Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance. Sci.Rep. 6, (2016).

A-381393 是选择性、可透过血脑屏障的多巴胺 D4受体拮抗剂，对人多巴胺 D4.4，D4.2和 D4.7受体的 Ki 分别为 1.5，1.9 和 1.6 nM，选择性是对 D1，D2，D3，D5多巴胺受体的 2700 多倍，对 5-HT2A 的选择性适中，Ki=370 nM。